"Prior to such license fees and related costs, annual fiscal income for Q4 was $7,222,000 or $0.22 per share and $29,659,000 or $0.89 per share for FY98."
Don't these one time licensing fees count as a charge, and then the earnings would be as above: Q4 $0.22 and FY98 $0.89.?
Fiscal 98 net income of $13,154,000 or $0.40 on total revenue of $466,505,000.
Including charges or license fees, 4th quarter net loss of ($8,923,000) or ($.29) per share, reflecting the licensing fees of $26,000,000 for 3 development stage products.
Fiscal 98 sales of Viracept were $409,298,000 which included sales in the U.S. of $358,321,000.
Total Viracept 4Q sales were $126,046.000. - a 13% increase from the immediate preceding QUARTER.
Q4 sales for the US were $105,633,000.
Sales of Viracept outside of the US were $51,000,000.
Prior year Q4 and FY97 was losses -net income of ($10,804,000) was ($0.38) and ($42,806,000.) ($1.59).
The company also announced its intention to create a separate operating division in which the company's research and development of products for oncology and related fields will be conducted. UNder the proposed plan, which must be approved by shareholders, the financial performance of this oncology R&D division would be traced by a separate divisional stock. |
